病例分享:不明原因的肝病,居然是这种癌!

2017-12-14 谭友文 医学界消化肝病频道

在肝脏疾病的诊治过程中,最常让肝科医师头痛的是“不明原因肝病”,这些病人常出现肝病不适的症状,如乏力、食欲下降、尿黄等,关键是肝功能常有异常的转氨酶,更有甚者B超、CT等还明确提示慢性肝损、肝硬化等病变。

在肝脏疾病的诊治过程中,最常让肝科医师头痛的是“不明原因肝病”,这些病人常出现肝病不适的症状,如乏力、食欲下降、尿黄等,关键是肝功能常有异常的转氨酶,更有甚者B超、CT等还明确提示慢性肝损、肝硬化等病变。

让医生头痛的当然不是这些异常结果,刚好相反是那些常见的导致肝脏病变原因的各种化验单、检测单是正常的,如无甲~戊型病毒性肝炎、无自身免疫性抗体阳性、无酒精脂肪肝等病史、无毒、药物史等。当该查的查了,该做的也做了,还不知道原因,对这样的结果,医生忧闷,病人更是不满意!

病例分享

最近我们就遇一例,一位男性,72岁,出现肝功能异常,ALT、GGT高出正常值10倍,有黄疸,B超和CT提示肝脏有萎缩,间隙增宽,该病人有多年饮酒史,很容易让医生诊断酒精性肝病,但B超、CT并不是太支持酒精肝的特点,酒精肝一般是肝肿大,该病人是缩小。为明确诊断,建议病人进行肝组织学检查。



HE染色



Masson染色

果然病理没看到典型的酒精性肝损特点,无肝细胞脂肪样变,无严重气球样变等酒精肝损伤特点,但却看到了一个不常见的汇管区变化,可见到异常畸形的胆管,单层柱状上皮,呈囊性增生,周围纤维化环绕。原来这是胆管错构瘤。



CT未发现明显的囊性病变

胆管错构瘤的形成

肝内胆管错构瘤(Bile duct hamartomas in liver,LBDH)是一种少见的肝脏病变,由Von Meyenburg于1918年首先描述,故又称von Meyenburg complexes综合征(VMC),被认为是由于正常胆管的原始管板(胚胎胆管)发育阻滞或异常所致的错构性病。

人胚4周初:前肠末端腹侧壁的上皮增生,向外长出一囊状突起,称肝憩室(hepatic diverticu1um),是肝与胆的原基。肝憩室迅速增大,长入原始横隔,其末端膨大,并分为头、尾两支。头支是形成肝的原基,尾支是形成胆囊及胆道的原基。头支很快形成树芽状分支,尾支发育成胆囊和胆囊管,肝憩室的根部发育成总胆管。

由于未知的原因,由胚胎时期肝内胆管发育过程被扰乱或停滞所致。胚胎时期,肝内胆管从肝门部向远端重塑,该病变发生于该过程的较晚阶段,因此病变多表现为小的、外周及小叶内胆管的纤维化。



胆管错构瘤的形成

胆管错构瘤的诊断

错构瘤多无明显临床症状,实验室检查无特异度,部分患者可出现转氨酶、胆红素异常,但血AFP和CEA一般正常。患者多合并胆囊结石、胰腺炎及阑尾炎等其他疾病,胆管错构瘤为偶然发现,胆管错构瘤的诊断金标准为MRI及病理,但由于该病为无明显临床表现的良性病变,多无需接受手术治疗或穿刺活检,故临床上该病多经MRI确诊。

MRI表现

平扫呈长T1长T2改变,T1WI显示病变信号略低于肝实质,T2wI病灶显示清楚,呈明显高信号,增强扫描未见明显强化,部分病灶可见环形强化或结节状强化,MRCP显示病变与肝内胆管不相通。

病理特点

沿肝内毛细胆管分布的囊性结构,直径多数<1.5 cm,大小近似,遍布全肝,偶有单发病变报道,此囊性结构形态不规则,与周围胆管不相通,囊壁由单层立方或扁平的胆管上皮细胞构成,周围绕以纤维组织及胆管周围腺体,腔内可包含嗜酸性纤维。

胆管错构瘤的鉴别诊断

主要鉴别诊断包括:

(1) 肝囊肿:普通囊肿大小不一,囊壁菲薄,分布无规律,圆形多见,边缘光整,不合并多发点状强回声伴彗星尾征及高回声小结节;

(2) 肝实质弥漫性病变:多有慢性肝病病史,加压扫查显示肝脏质地较硬,多不合并肝内点状强回声伴彗星尾征;

(3) Caroli病:为肝内胆管非梗阻性扩张,也表现为沿胆管分布的囊性病变,但病变与胆管相通,而胆管错构瘤与胆管不相通,且多合并肝内点状强回声伴彗星尾征及高回声小结节;

(4) 肝多发血管瘤:超声上也可表现为多发高回声小结节,但多不合并不规则,小囊性病变及点状强回声伴彗星尾征;

(5) 肝内多发转移瘤:如表现为高回声小结节,则与胆管错构瘤较难鉴别,但后者多小而弥漫,最终需病理证实。

胆管错构瘤多无临床症状,预后良好,但也有研究认为该病与其他疾病相关,如胆管癌、复发性胆管炎、严重门脉高压等。所以,对于胆管错构瘤的识别具有重要意义,而MRI可作为首选的筛查方式。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=272312, encodeId=54332e2312e1, content=不明原因的肝病., beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Dec 25 07:28:19 CST 2017, time=2017-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=270014, encodeId=e83e2e0014bb, content=读透分享病例., beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Dec 17 07:33:21 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269958, encodeId=e899269958b1, content=学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Dec 17 00:45:44 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269551, encodeId=0c98269551ce, content=学习了.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Fri Dec 15 10:32:31 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269464, encodeId=c2bd26946454, content=学习了很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Dec 15 01:02:22 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269462, encodeId=cdf9269462f7, content=见识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Fri Dec 15 00:22:41 CST 2017, time=2017-12-15, status=1, ipAttribution=)]
    2017-12-25 jyzxjiangqin

    不明原因的肝病.

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=272312, encodeId=54332e2312e1, content=不明原因的肝病., beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Dec 25 07:28:19 CST 2017, time=2017-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=270014, encodeId=e83e2e0014bb, content=读透分享病例., beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Dec 17 07:33:21 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269958, encodeId=e899269958b1, content=学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Dec 17 00:45:44 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269551, encodeId=0c98269551ce, content=学习了.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Fri Dec 15 10:32:31 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269464, encodeId=c2bd26946454, content=学习了很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Dec 15 01:02:22 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269462, encodeId=cdf9269462f7, content=见识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Fri Dec 15 00:22:41 CST 2017, time=2017-12-15, status=1, ipAttribution=)]
    2017-12-17 jyzxjiangqin

    读透分享病例.

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=272312, encodeId=54332e2312e1, content=不明原因的肝病., beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Dec 25 07:28:19 CST 2017, time=2017-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=270014, encodeId=e83e2e0014bb, content=读透分享病例., beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Dec 17 07:33:21 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269958, encodeId=e899269958b1, content=学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Dec 17 00:45:44 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269551, encodeId=0c98269551ce, content=学习了.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Fri Dec 15 10:32:31 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269464, encodeId=c2bd26946454, content=学习了很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Dec 15 01:02:22 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269462, encodeId=cdf9269462f7, content=见识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Fri Dec 15 00:22:41 CST 2017, time=2017-12-15, status=1, ipAttribution=)]
    2017-12-17 1209e435m98(暂无昵称)

    学习了.谢谢分享!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=272312, encodeId=54332e2312e1, content=不明原因的肝病., beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Dec 25 07:28:19 CST 2017, time=2017-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=270014, encodeId=e83e2e0014bb, content=读透分享病例., beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Dec 17 07:33:21 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269958, encodeId=e899269958b1, content=学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Dec 17 00:45:44 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269551, encodeId=0c98269551ce, content=学习了.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Fri Dec 15 10:32:31 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269464, encodeId=c2bd26946454, content=学习了很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Dec 15 01:02:22 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269462, encodeId=cdf9269462f7, content=见识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Fri Dec 15 00:22:41 CST 2017, time=2017-12-15, status=1, ipAttribution=)]
    2017-12-15 明天会更好!

    学习了.学习了.

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=272312, encodeId=54332e2312e1, content=不明原因的肝病., beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Dec 25 07:28:19 CST 2017, time=2017-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=270014, encodeId=e83e2e0014bb, content=读透分享病例., beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Dec 17 07:33:21 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269958, encodeId=e899269958b1, content=学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Dec 17 00:45:44 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269551, encodeId=0c98269551ce, content=学习了.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Fri Dec 15 10:32:31 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269464, encodeId=c2bd26946454, content=学习了很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Dec 15 01:02:22 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269462, encodeId=cdf9269462f7, content=见识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Fri Dec 15 00:22:41 CST 2017, time=2017-12-15, status=1, ipAttribution=)]
    2017-12-15 飛歌

    学习了很有用

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=272312, encodeId=54332e2312e1, content=不明原因的肝病., beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Dec 25 07:28:19 CST 2017, time=2017-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=270014, encodeId=e83e2e0014bb, content=读透分享病例., beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Dec 17 07:33:21 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269958, encodeId=e899269958b1, content=学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Dec 17 00:45:44 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269551, encodeId=0c98269551ce, content=学习了.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Fri Dec 15 10:32:31 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269464, encodeId=c2bd26946454, content=学习了很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Dec 15 01:02:22 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269462, encodeId=cdf9269462f7, content=见识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Fri Dec 15 00:22:41 CST 2017, time=2017-12-15, status=1, ipAttribution=)]
    2017-12-15 smartxiuxiu

    见识了

    0

相关资讯

AASLD中国之声:聚焦多领域,多项成果在会上展示

第68届美国肝病研究学会(AASLD)年会上,贾继东教授及尤红教授团队带来了涵盖慢性乙型肝炎、原发性胆汁性胆管炎、药物性肝损伤、遗传性血色病以及肝纤维化/肝硬化的多项基础和临床研究成果,内容丰富,覆盖面广。快快跟随小编一起看看都有哪些精彩内容!

J Invest Dermatol:警惕:牛皮癣可能使你患上严重肝病!

与对照组相比,牛皮癣患者(PsO)的严重肝脏疾病的风险要高于类风湿性关节炎患者 - 这两种自身免疫性疾病常常用类似的药物治疗,可引起肝损伤,本周在“调查性皮肤病学杂志”宾夕法尼亚大学佩雷尔曼医学院的研究人员发表了此研究。该研究是第一个基于人群的研究,同时解决这些炎症性疾病和牛皮癣关节炎(PsA)患者肝脏疾病的风险,在超过197,000个PsO患者,12,000个PsA患者,54,000个类风湿性关

Aliment Pharm Therap:肝病患者服用β受体阻滞剂 哪项心肺运动测试不受影响?

2017年10月,发表在《Aliment Pharmacol Ther》的一项由澳大利亚和美国科学家进行的横断面分析,考察了β受体阻滞剂对晚期肝病患者心肺运动测试的影响。

Nat Commun:肝病患者的救星,科学家发现肝脏疾病的治疗关键

科学家已经确定了血管中的一个关键基因,它可以提供一种新的方法来评估和治疗肝病。

胃病肝病如何防治?听专家讲科普

胃痛、胃胀、胃酸反流……生活中,人们或多或少都遇到过胃不舒服的状况。胃病作为一种“常见病”总能引发不少人的共鸣。近日,2017上海台北双城健康讲坛暨第35届解放健康讲坛在台北市台湾金融研训院举行。两岸医学专家围绕胃、肝疾病,给大众提供了一系列预防、治疗的方法。保护肝脏牢记“六字”中国工程院院士、高雄长庚纪念医院名誉院长陈肇隆介绍,肝脏是人体最大最重的器官,也是非常繁忙的化学工厂。在台湾,每年约有7

Nat Commun:普通酸回流药物可引发并加重慢性肝病

一般人群中约有10%采用质子泵抑制剂(PPI)药物阻断胃酸分泌物,缓解胃灼热,酸反流和胃食管反流病频发的症状。慢性肝病患者的百分比可高达7倍。加利福尼亚大学圣地亚哥分校医学院的研究人员发现,小鼠和人类的胃部(胃)酸抑制作用可以通过促进肝脏损伤和三种慢性肝脏疾病进展的方法来改变特定的肠道细菌。